Plasma levels of microRNA-21, -126 and -423-5p alter during clinical improvement and are associated with the prognosis of acute heart failure

Schneider, S; Silvello, Daiane; Martinelli, Nidiane Carla; Garbin, Arthur Pereira; Biolo, Andréia; Clausell, Nadine Oliveira; Andrades, Michael Éverton; Santos, Kátia Gonçalves dos; Rohde, Luís Eduardo Paim

doi:10.3892/mmr.2018.8428

Cited by 22 publications

(28 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In combination with other researchers 'statistics on sample size, we selected more than 60 healthy samples and more than 60 cases of heart failure. Exhaustion samples were analyzed [21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38]. As shown in Figure 1, the aim of the present study was to identify circulating miRNAs in human plasma as biomarkers for the diagnosis of heart failure and its related diseases, to assess the appropriate biomarkers for identifying key characteristics of miRNAs, and to analyze their performance.…”

Section: Introductionmentioning

confidence: 99%

Combined detection of miR-21-5p, miR-30a-3p, miR-30a-5p, miR-155-5p, miR-216a and miR-217 for screening of early heart failure diseases

Ding

Wang

et al. 2020

Bioscience Reports

View full text Add to dashboard Cite

The use of circulating microRNAs as biomarkers opens up new opportunities for the diagnosis of cardiovascular diseases because of their specific expression profiles. The aim of the present study was to identify circulating microRNAs in human plasma as potential biomarkers of heart failure and related diseases. We used real-time quantitative PCR to screen mi-croRNA in plasma samples from 62 normal controls and 62 heart failure samples. We found that circulating miR-21-5p, miR-30a-3p, miR-30a-5p, miR-155-5p, miR-216a and miR-217 expressed differently between healthy controls and heart failure patients. Plasma levels of miR-21-5p, miR-30a-3p, miR-30a-5p, miR-155-5p, miR-216a and miR-217 were unaffected by hemolysis. Correlation analysis showed any two of these miRNAs possess a strong correlation, indicating a possibility of combined analysis. MiR-21-5p, miR-30a-3p, miR-30a-5p, miR-155-5p, miR-216a and miR-217 could be combined in two or three or more combinations. The results suggest that miR-21-5p, miR-30a-3p, miR-30a-5p, miR-155-5p, miR-216a and miR-217 may be a new diagnostic biomarker for heart failure and related diseases.

show abstract

Section: Introductionmentioning

confidence: 99%

Combined detection of miR-21-5p, miR-30a-3p, miR-30a-5p, miR-155-5p, miR-216a and miR-217 for screening of early heart failure diseases

Ding

Wang

et al. 2020

Bioscience Reports

View full text Add to dashboard Cite

show abstract

“…Aberrantly expressed miRNAs have been identified by increasing number of studies to be of high potential in the diagnosis and prognosis of CHD patients ( 8 , 9 ). Meanwhile, growing number of studies focusing on the role of miRNA in HF have reported that circulating miRNAs participate in the etiology of HF and are the potential biomarkers in HF patients ( 10 , 11 ). For instance, plasma miR-132 expression is independently associated with disease severity and hospitalization rate of HF patients ( 12 ).…”

Section: Introductionmentioning

confidence: 99%

Combination of PBMC miR-19b-5p, miR-221, miR-25-5p and hypertension correlates with increased risk of heart failure in coronary heart disease patients

Yao

Song

Xiong³

et al. 2018

Anatol J Cardiol

View full text Add to dashboard Cite

Objective:The aim of this study was to explore the differences in microRNA (miRNA) profiles in peripheral blood mononuclear cells (PBMCs) between coronary heart disease (CHD) patients with and without heart failure (HF) and to assess the values of differentially expressed miRNAs (DEMs) regarding HF risk in CHD patients.Methods:Six CHD patients with HF and six age- and gender-matched CHD patients without HF were enrolled in the exploration stage, and 44 CHD patients with HF and 42 age- and gender-matched CHD patients without HF were recruited in the validation stage. Peripheral blood samples were collected from all the participants, and PBMCs were separated for miRNA detection. miRNA microarray and quantitative polymerase chain reaction were performed to assess the miRNA expression.Results:In the exploration stage, heat map analysis showed that CHD patients with HF could be distinguished from those without HF using PMBC miRNA expressions; 63 downregulated DEMs and 84 upregulated DEMs in PBMCs were identified in CHD patients with HF using volcano map, and top 8 DEMs were selected based on their p values. In the validation stage, PBMC miR-221, miR-19b-5p, and miR-25-5p were found to be markedly dysregulated in CHD patients with HF. Multiple logistic regression analysis showed PBMC miR-221, miR-19b-5p, miR-25-5p, and hypertension to be the independent predictive factors for HF in CHD patients. A receiver operating characteristic curve demonstrated that area under curve of the combination of miR-221, miR-19b-5p, miR-25-5p, and hypertension was 0.871 (95% CI: 0.794-0.944).Conclusion:CHD patients with and without HF could be differentiated according to PBMC miRNA profiles, and the combination of PBMC miR-19b-5p, miR-221, miR-25-5p, and hypertension correlates with an increased HF risk in CHD patients.

show abstract

“…However, Zhang et al (10) demonstrated a signi cant correlation of miR-21 with patients' two-year mortality but not with readmission rate. Schneider et al (27) reported that increased level of miR-21 at the time of clinical compensation was associated with better two-year survival and longer rehospitalization-free. Furthermore, they demonstrated that higher miR-423-5p between the time of admission and clinical compensation was associated with fewer hospital readmissions in two-years.…”

Section: Discussionmentioning

confidence: 99%

Diagnostic and Prognostic Value of Selected MicroRNAs in Patients with Acute Heart Failure

Sadat-Ebrahimi¹,

Aslanabadi²,

Asadi³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Measurement of the level of circulating microRNAs (miRNAs) has been introduced as a convincing diagnostic modality in a variety of diseases including acute heart failure (AHF). There are also a few encouraging results that advocate the prognostic value of miRNAs in AHF. Our aim in this study was to evaluate the diagnostic and prognostic value of selected miRNAs in patients with AHF. Method: Forty-four patients were randomly selected from AHF patients attending the Madani Heart Center of the Tabriz University of Medical Sciences from 1st April 2018 to 31st August 2018. 58 healthy participants were included as the control group. The plasma level of selected miRNAs including miR -1, -21, -23, and -423-5-p were measured in both groups. In the second phase, patients were followed for one year and several outcomes were recorded including in-hospital mortality, one-year mortality, and the number of readmissions. Result: An overall 102 plasma samples were evaluated. There was no significant difference in demographic characteristics between the two groups (p> 0.05). Mean levels of miR-1, -21, -23, and -423-5-p in AHF patients were significantly higher than the control group (p values=0.001, 0.002, 0.002, and 0.001, respectively). All selected miRNAs demonstrated high diagnostic power. The highest sensitivity and specificity were seen in miR-423-5-p which were 90% and >99%, respectively (p = 0.001, AUC = 0.909). The follow-up data demonstrated these miRNAs had no significant association with prognostic outcomes (p>0.05 for all variables). Conclusion: The result of our study demonstrated that miR-1, -21, -23, and -423-5-p can be considered as biomarkers with high sensitivity and specificity in AHF. However, we found no evidence supporting the efficacy of these miRNAs as prognostic factors.

show abstract

Plasma levels of microRNA-21, -126 and -423-5p alter during clinical improvement and are associated with the prognosis of acute heart failure

Cited by 22 publications

References 36 publications

Combined detection of miR-21-5p, miR-30a-3p, miR-30a-5p, miR-155-5p, miR-216a and miR-217 for screening of early heart failure diseases

Combined detection of miR-21-5p, miR-30a-3p, miR-30a-5p, miR-155-5p, miR-216a and miR-217 for screening of early heart failure diseases

Combination of PBMC miR-19b-5p, miR-221, miR-25-5p and hypertension correlates with increased risk of heart failure in coronary heart disease patients

Diagnostic and Prognostic Value of Selected MicroRNAs in Patients with Acute Heart Failure

Contact Info

Product

Resources

About